Posted On: 10/06/2016 2:37:07 AM
Post# of 658
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
8.87+1.85 (+26.35%)
Day's Range 7.50 - 9.78
Volume 13,393,432
Avg Vol (3m) 886,124
keep an eye on those date
Additionally, Corbus also plans to reveal the initial efficacy for three new orphan drugs, the first in November, followed by the second in January 2017 and the last in the second half of 2017.
Cantor estimates the market potential of these orphan drugs is around $3 billion.
About 12.91 million shares of the stock have traded on Wednesday vs. the 30-day average volume of about 1.15 million shares.
8.87+1.85 (+26.35%)
Day's Range 7.50 - 9.78
Volume 13,393,432
Avg Vol (3m) 886,124
Quote:
NEW YORK (TheStreet) -- Shares of Corbus Pharmaceuticals (CRBP) closed up 25.75% to $8.83 on Wednesday as coverage of the stock was started with a "buy" rating and $17 price target at Cantor Fitzgerald earlier today.
The firm said that the Norwood, MA-based pharmaceutical company will reach several clinical inflection points in the next year.
The company will present data on its lead candidate resunab for chronic inflammation next month. The drug has previously shown "encouraging" results, Cantor notes.
The firm added that Corbus has filed patents for a specific formulation of resunab that could give the drug protection from general versions until 2033.
keep an eye on those date
Additionally, Corbus also plans to reveal the initial efficacy for three new orphan drugs, the first in November, followed by the second in January 2017 and the last in the second half of 2017.
Cantor estimates the market potential of these orphan drugs is around $3 billion.
About 12.91 million shares of the stock have traded on Wednesday vs. the 30-day average volume of about 1.15 million shares.
(0)
(0)
my "home" come for a visit here
Don't be afraid to be outnumbered. Pigeons flock together. Eagle fly alone
Don't be afraid to be outnumbered. Pigeons flock together. Eagle fly alone
